Bayer AG (FRA:BAYA) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BAYA Bayer AG FRA:BAYA
60 GF Score
Price €12.20
GF Value €6.56
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Bayer AG Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:BAYA
60GF Score
Bayer AG FRA:BAYA
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bayer AG (FRA:BAYA) Overvalued in 2026?

Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued. The current stock price of €12.20 is trading 86% above its estimated GF Value™ of €6.56. GuruFocus considers Bayer AG to be Significantly Overvalued.

Key valuation signals for FRA:BAYA:

  • Interest Received:
  • GF Value™: €6.56 vs. price of €12.20 (86% above fair value)
  • GF Score™: 60/100 with 7 warning signs

No single metric tells the full story. See the FRA:BAYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bayer AG Business Description

Address Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
60GF Score

Get the complete analysis for FRA:BAYA

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.20
Price
€6.56
GF Value